Hemophilia A

FDA Approval Gained for Recombinant Therapy

Published in Blood Weekly, March 30th, 2000

ReFacto Antihemophilic Factor (Recombinant), a therapy for hemophilia A from American Home Products Corp., Madison, New Jersey, has been approved for marketing by the U.S. Food and Drug Administration (FDA).

ReFacto was developed by the Genetics Institute of Wyeth-Ayerst Laboratories, the pharmaceutical division of American Home Products. ReFacto Antihemophilic Factor (Recombinant) is the first recombinant factor VIII product formulated without human serum albumin to be approved by the FDA. ReFacto is indicated for the control and prevention of bleeding episodes and surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2000-03-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry